| Inhibition of PI3K signaling spurs new therapeutic opportunities in inflammatory/autoimmune diseases and hematological malignancies JG Foster, MD Blunt, E Carter, SG Ward Pharmacological reviews 64 (4), 1027-1054, 2012 | 155 | 2012 |
| IL-4 enhances expression and function of surface IgM in CLL cells MM Aguilar-Hernandez, MD Blunt, R Dobson, A Yeomans, ... Blood, The Journal of the American Society of Hematology 127 (24), 3015-3025, 2016 | 120 | 2016 |
| The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mcl-1 M Larrayoz, SJ Blakemore, RC Dobson, MD Blunt, MJJ Rose-Zerilli, ... Leukemia 30 (2), 351-360, 2016 | 113 | 2016 |
| The dual Syk/JAK inhibitor cerdulatinib antagonizes B-cell receptor and microenvironmental signaling in chronic lymphocytic leukemia MD Blunt, S Koehrer, RC Dobson, M Larrayoz, S Wilmore, A Hayman, ... Clinical Cancer Research 23 (9), 2313-2324, 2017 | 71 | 2017 |
| Activating killer cell immunoglobulin‐like receptors: detection, function and therapeutic use MD Blunt, SI Khakoo International Journal of Immunogenetics 47 (1), 1-12, 2020 | 67 | 2020 |
| The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Eµ-TCL1 mouse model MD Blunt, MJ Carter, M Larrayoz, LD Smith, M Aguilar-Hernandez, ... Blood, The Journal of the American Society of Hematology 125 (26), 4032-4041, 2015 | 51 | 2015 |
| Targeting PI3K isoforms and SHIP in the immune system: new therapeutics for inflammation and leukemia MD Blunt, SG Ward Current Opinion in Pharmacology 12 (4), 444-451, 2012 | 43 | 2012 |
| Disruption of the NKG2A: HLA-E immune checkpoint axis to enhance NK cell activation against cancer JG Fisher, ADP Doyle, LV Graham, SI Khakoo, MD Blunt Vaccines 10 (12), 1993, 2022 | 33 | 2022 |
| Evidence that the lipid phosphatase SHIP-1 regulates T lymphocyte morphology and motility SJ Harris, RV Parry, JG Foster, MD Blunt, A Wang, F Marelli-Berg, ... The Journal of Immunology 186 (8), 4936-4945, 2011 | 33 | 2011 |
| Pharmacological targeting of phosphoinositide lipid kinases and phosphatases in the immune system: success, disappointment, and new opportunities MD Blunt, SG Ward Frontiers in Immunology 3, 226, 2012 | 29 | 2012 |
| Constitutive activation of natural killer cells in primary biliary cholangitis TJ Hydes, MD Blunt, J Naftel, AF Vallejo, G Seumois, A Wang, ... Frontiers in Immunology 10, 2633, 2019 | 26 | 2019 |
| Hydrogen peroxide triggers a dual signaling axis to selectively suppress activated human T lymphocyte migration JA Ball, I Vlisidou, MD Blunt, W Wood, SG Ward The Journal of Immunology 198 (9), 3679-3689, 2017 | 21 | 2017 |
| Peptide: MHC-based DNA vaccination strategy to activate natural killer cells by targeting killer cell immunoglobulin-like receptors P Rettman, MD Blunt, RJ Fulton, AF Vallejo, LY Bastidas-Legarda, ... Journal for Immunotherapy of Cancer 9 (5), 2021 | 18 | 2021 |
| Pharmacological targeting of PI3K isoforms as a therapeutic strategy in chronic lymphocytic leukaemia MD Blunt, AJ Steele Leukemia Research Reports 4 (2), 60-63, 2015 | 18 | 2015 |
| Selinexor Enhances NK Cell Activation Against Malignant B Cells via Downregulation of HLA-E JG Fisher, CJ Walker, ADP Doyle, PWM Johnson, F Forconi, MS Cragg, ... Frontiers in oncology 11, 785635, 2021 | 17 | 2021 |
| BCR signaling contributes to autophagy regulation in chronic lymphocytic leukemia LD Smith, AR Minton, MD Blunt, LI Karydis, DA Dutton, ... Leukemia 34 (2), 640-644, 2020 | 15 | 2020 |
| KIR2DS2 expression identifies NK cells with enhanced anticancer activity MD Blunt, A Vallejo Pulido, JG Fisher, LV Graham, ADP Doyle, R Fulton, ... The Journal of Immunology 209 (2), 379-390, 2022 | 11 | 2022 |
| A novel antibody combination to identify KIR2DS2high natural killer cells in KIR2DL3/L2/S2 heterozygous donors MD Blunt, P Rettman, LY Bastidas‐Legarda, R Fulton, V Capizzuto, ... Hla 93 (1), 32-35, 2019 | 11 | 2019 |
| Harnessing natural killer cell effector function against cancer MD Blunt, SI Khakoo Immunotherapy Advances 4 (1), ltad031, 2024 | 8 | 2024 |
| XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression JG Fisher, ADP Doyle, LV Graham, S Sonar, B Sale, I Henderson, ... Leukemia 37 (10), 2036-2049, 2023 | 7 | 2023 |
